These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3079030)

  • 1. Relationship between cellular and molecular markers of inflammation in human kidney allograft rejection.
    von Willebrand E; Häyry P
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1644-5. PubMed ID: 3079030
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal target structures in acute allograft rejection.
    Leszczynski D; Laszczynska M; Halttunen J
    Transplant Proc; 1987 Feb; 19(1 Pt 1):378. PubMed ID: 3079159
    [No Abstract]   [Full Text] [Related]  

  • 3. HLA class II and IL-2R expression in acute vascular rejection of human kidney allografts.
    von Willebrand E; Salmela K; Isoniemi H; Taskinen E; Krogerus L; Häyry P
    Transplant Proc; 1992 Feb; 24(1):303-4. PubMed ID: 1539286
    [No Abstract]   [Full Text] [Related]  

  • 4. Pre-operative interleukin 2 and interleukin 2 receptor levels may predict subsequent renal allograft rejection.
    Cornaby AJ; Simpson MA; Madras PN; Dempsey RA; Clowes GH; Monaco AP
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1861-2. PubMed ID: 2652604
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of serum immunological parameters in acute renal allograft rejection.
    Yang J; Li XW; Zheng FL; Bi ZQ
    Transplant Proc; 1996 Jun; 28(3):1443-4. PubMed ID: 8658732
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression of class I and class II major histocompatibility complex (MHC) antigens in rejecting human heart grafts.
    Ippoliti G; Lazzaro A; Goggi C; Malavasi F; Di Franco L; Martinelli L; Ascari E; Vigano' M
    Transplant Proc; 1989 Feb; 21(1 Pt 1):445-6. PubMed ID: 2650172
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular activation markers in rejection diagnosis.
    von Willebrand E; Häyry P; Taskinen E
    Transplant Proc; 1996 Feb; 28(1):484-5. PubMed ID: 8644321
    [No Abstract]   [Full Text] [Related]  

  • 8. In vivo immunosuppressive effect of purine nucleoside phosphorylase inhibitor-8-amino-9-benzyl-guanine in canine renal allograft rejection.
    Lin CY; Yen CY
    Transplant Proc; 1994 Dec; 26(6):3126-7. PubMed ID: 7998091
    [No Abstract]   [Full Text] [Related]  

  • 9. Functional characterization of renal infiltrating cells following allograft nephrectomy.
    Nikaein A; McQueen K; Boyer B; Landesberg R; Ryan DH; Insel RA
    Transplant Proc; 1987 Feb; 19(1 Pt 1):398-400. PubMed ID: 3274792
    [No Abstract]   [Full Text] [Related]  

  • 10. CD4 monoclonal antibodies in the preclinical dog renal allograft model.
    Watson CJ; Davies HS; Metcalfe SM; Cobbold SP; Rebello PR; Collier DS; Waldmann H; Calne RY
    Transplant Proc; 1993 Feb; 25(1 Pt 1):804-6. PubMed ID: 8438491
    [No Abstract]   [Full Text] [Related]  

  • 11. Usefulness of serum interleukin 2 receptor levels in renal allograft recipients.
    Plaza JJ; Blum G; Ortiz A; Hernando L; Feijoo E; Sanz J; Garcia R; Egido J; Ortiz F
    Transplant Proc; 1992 Feb; 24(1):63-4. PubMed ID: 1539346
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma soluble interleukin-2 receptor (IL-2RS) level and activation markers in blood in the follow-up of renal allograft patients.
    Malcus C; Pouteil-Noble C; Touraine F; Raffaele P; Touraine JL
    Transplant Proc; 1990 Aug; 22(4):1865-6. PubMed ID: 2389463
    [No Abstract]   [Full Text] [Related]  

  • 13. Class II antigens and interleukin 2 expression in renal allograft recipients.
    Glapinski T; Lao M; Wasik M; Lagodzinski Z; Nowaczyk M; Gorski A
    Transplant Proc; 1989 Feb; 21(1 Pt 1):319. PubMed ID: 2650133
    [No Abstract]   [Full Text] [Related]  

  • 14. Soluble CD23 and interleukin-2 receptor levels in renal allograft recipients.
    Beksaç M; Dalva K; Gönenç F; Dalva I; Gariboğlu S; Batur N; Cetin S
    Transplant Proc; 1993 Apr; 25(2):2145-7. PubMed ID: 8470296
    [No Abstract]   [Full Text] [Related]  

  • 15. BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejection.
    Mueller AR; Platz KP; Steinmüller T; Nüssler N; Neumann U; Gerlach H; Stoll C; Bechstein WO; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3103-5. PubMed ID: 8962203
    [No Abstract]   [Full Text] [Related]  

  • 16. Activation antigen expression on peripheral blood neutrophils: a novel marker of rejection following rat small bowel transplantation.
    Webster GA; Bowles MJ; Karim MS; Wood RF; Pockley AG
    Transplant Proc; 1994 Jun; 26(3):1522. PubMed ID: 8030019
    [No Abstract]   [Full Text] [Related]  

  • 17. Correlation of HLA class II antigen induction and cellular infiltration in renal allograft rejection.
    McWhinnie DL; Fuggle SV; Azevedo LS; Carter NP; Morris PJ
    Transplant Proc; 1989 Feb; 21(1 Pt 1):320-1. PubMed ID: 2650134
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of interferon alpha in allograft rejection.
    Benizri EJ; Gugenheim J; Bernard G; Tovey MG
    Transplant Proc; 1995 Feb; 27(1):413. PubMed ID: 7879043
    [No Abstract]   [Full Text] [Related]  

  • 19. Expression of adhesion molecules in allograft renal dysfunction: a distinct diagnostic pattern in rejection and cyclosporine nephrotoxicity.
    Mampaso F; Marcen R; Molina A; Pascual J; Martin A; Bricio T
    Transplant Proc; 1994 Oct; 26(5):2859-60. PubMed ID: 7524222
    [No Abstract]   [Full Text] [Related]  

  • 20. Elevation of serum C-reactive protein levels during graft rejection.
    Lempert N; Laffin RJ; Fitzgerald K; Freed BM
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1683-5. PubMed ID: 3274404
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.